Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $118.15 | Total: $590.75 |
| 1 | 10 | $100.08 | Total: $1,000.80 |
| 1 | 25 | $84.79 | Total: $2,119.75 |
| 1 | 50 | $72.28 | Total: $3,614.00 |
| 1 | 100 | $62.55 | Total: $6,255.00 |
Overview
VEGFR-3-IN-1 is a novel, potent, and selective VEGFR3 inhibitor with an IC50 of 110.4 nM. It exhibits antitumor activity, inactivates the VEGFR3 signaling pathway, and inhibits the proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231, and MDA-MB-436 cells.
Chemical Properties
| Molecular Formula | C29H29ClF3N7OS |
| Molecular Weight | 616.1 |
| CAS Numbers | 2756668-73-0 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C(NC1=CC(C(F)(F)F)=C(Cl)C=C1)(=O)N2CCN(C3=C4C(SC(=C4)C5=CC=C(C=C5)N6CCN(C)CC6)=NC=N3)CC2 |
Storage and Handling
0C Short Term, -20C Long Term
References
Li Y, et al. Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 [VEGFR3] Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer. J Med Chem. 2021 Aug 26;64[16] 12022-12048.